news_image.jpg

Prostate cancer treatment rejected in England and Wales

07 Jan 2022


The National Institute for Health and Care Excellence (NICE) has rejected olaparib as a routine treatment for hormone-relapsed metastatic prostate cancer, due to high costs.

Medscape